Skip to main content
SpringerLink
Log in

Diabetes and Heart Failure

  • Chapter
  • First Online:
Managing Heart Failure in Primary Care: A Case Study Approach

  • 500 Accesses

Abstract

Type 2 diabetes mellitus (T2DM) is commonly encountered in primary care, and heart failure (HF) is a significant cardiovascular complication of T2DM. Primary care providers are important members of the team for patients with T2DM and HF. This chapter will outline special considerations when caring for this population and treatment options that may have additional benefits or risks for patients with T2DM and HF.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Marwick TH, Ritchie R, Shaw JE, Kaye D. Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. J Am Coll Cardiol. 2018;71(3):339–51. https://doi.org/10.1016/j.jacc.2017.11.019.

    Article  PubMed  Google Scholar 

  2. Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS, Deswal A, Dickson VV, Kosiborod MN, Lekavich CL, McCoy RG, Mentz RJ, Piña IL, On behalf of the American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and the Heart Failure Society of America. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019;140(7):e294–324. Available https://www.ahajournals.org/doi/epub/10.1161/CIR.0000000000000691.

    Article  CAS  PubMed  Google Scholar 

  3. Oktay AA, Aktürk HK, Paul TK, et al. Diabetes, cardiomyopathy, and heart failure. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext. South Dartmouth: MDText.com, Inc.; 2000. Available from https://www.ncbi.nlm.nih.gov/sites/books/NBK560257/.

    Google Scholar 

  4. Shaw JA, Cooper ME. Contemporary management of heart failure in patients with diabetes. Diabetes Care. 2020;43(12):2895–903. https://doi.org/10.2337/dc20-2173.

    Article  CAS  PubMed  Google Scholar 

  5. Nassif ME, Kosiborod M. A review of cardiovascular outcomes trials of glucose-lowering therapies and their effects on heart failure outcomes. Am J Cardiol. 2019;124(Suppl 1):S12–9. https://doi.org/10.1016/j.amjcard.2019.10.025.

    Article  CAS  PubMed  Google Scholar 

  6. Centers for Disease Control and Prevention. National diabetes statistics report, 2020. Atlanta: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2020. Available https://www.cdc.gov/diabetes/library/socialmedia/infographics/diabetes.html.

    Google Scholar 

  7. DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36(2):S127–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–9.

    Article  PubMed  Google Scholar 

  9. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. American Diabetes Association. Standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1): S1–S232. Retrieved from: https://diabetesjournals.org/care/issue/44/Supplement_1.

    Google Scholar 

  11. Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm–2020 executive summary. Endocr Pract. 2020;26(1):107–139. https://doi.org/10.4158/CS-2019-0472.

    Article  PubMed  Google Scholar 

  12. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015;21(Suppl 1):1–87.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Hanefeld M, Frier BM, Pistrosch F. Hypoglycemia and cardiovascular risk: is there a major link? Diabetes Care. 2016;39(Suppl 2):S205–9. https://doi.org/10.2337/dcS15-3014.

    Article  CAS  PubMed  Google Scholar 

  14. George CM, Brujin LL, Will K, Howard-Thompson A. Management of blood glucose with noninsulin therapies in type 2 diabetes. Am Fam Physician. 2015;92(1):27–34.

    PubMed  Google Scholar 

  15. Author. Drugs for type 2 diabetes. Med Lett Drugs Ther. 2019;61(1584):169–78.

    Google Scholar 

  16. Domecq JP, Prutsky G, Leppin A, et al. Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100(2):363370.

    Article  Google Scholar 

  17. United States Food and Drug Administration. FDA drug safety communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. 2017. Accessed 1 July 2021. Available http://www.fda.gov/Drugs/DrugSafety/ucm493244.htm.

  18. United States Food and Drug Administration. FDA drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood and serious urinary tract infections. 2020. https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious.

  19. United States Food and Drug Administration. FDA drug safety communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. 2015. Available http://www.fda.gov/Drugs/DrugSafety/ucm459579.htm.

  20. United States Food and Drug Administration. Prescribing Information for Onglyza (saxagliptin). 2017. Accessed February 16, 2022. Available https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022350s018lbl.pdf.

  21. United States Food and Drug Administration. Prescribing information for nesina (alogliptin). 2016. Accessed July 5, 2021. Available https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022271s011lbl.pdf.

  22. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–e1032.

    PubMed  Google Scholar 

  23. United States Food and Drug Administration. FDA Drug Safety Communication: updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer. 2016. Available https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-updated-fda-review-concludes-use-type-2-diabetes-medicine-pioglitazone.

  24. United States Food and Drug Administration. FDA drug safety communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. 2015. Accessed 6 July 2021. Available https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-label-diabetes-drug-canagliflozin-invokana-invokamet.

  25. Zhou Z, Jardine M, Perkovic V, et al. Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. Diabetologia. 2019;62(10):1854–67. https://doi.org/10.1007/s00125-019-4955-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Epocrates. Clinical drug reference- mobile application for iOS. Accessed 28 June 2021.

    Google Scholar 

  27. Maddox TM, Januzzi JL Jr, et al. 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;77(6):772–810. https://doi.org/10.1016/j.jacc.2020.11.022.

    Article  PubMed  Google Scholar 

  28. Petrie JR, Rossing PR, Campbell IW. Metformin and cardiorenal outcomes in diabetes: a reappraisal. Diabetes Obes Metab. 2020;22(6):904–15. https://doi.org/10.1111/dom.13984.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Lexicomp/UptoDate. Available www.uptodate.com.

  30. Handelsman Y, Henry R, Bloomgarden ZT, DeFronzo RA, et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract. 2016;22(6):753–62.

    Article  PubMed  Google Scholar 

  31. United States Food and Drug Administration. FDA drug safety communication: FDA eliminates the risk evaluation and mitigation strategy (REMS) for rosiglitazone-containing diabetes medicines. 2015. Accessed 2 July 2021. Available http://www.fda.gov/Drugs/DrugSafety/ucm476466.htm.

  32. DeFronzo RA, Triplitt CL, Abdul-Ghani M, Cersosimo E. Novel agents for the treatment of type 2 diabetes. Diabetes Spectr. 2014;27(2):100–12.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Rojas P, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 2013;5(1):6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab. 2014;20(6):953–66.

    Article  CAS  PubMed  Google Scholar 

  35. United States Food and Drug Administration. FDA drug safety communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). 2016. Accessed 1 July 2021. Available http://www.fda.gov/Drugs/DrugSafety/ucm505860.htm.

  36. Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia. 2017;60:1385–9.

    Article  CAS  PubMed  Google Scholar 

  37. Umpierrez GE. Diabetes: SGLT2 inhibitors and diabetic ketoacidosis—a growing concern. Nat Rev Endocrinol. 2017;13:441–2.

    Article  CAS  PubMed  Google Scholar 

  38. Page KA, Reisman T. Interventions to preserve beta-cell function in the management and prevention of type 2 diabetes. Curr Diab Rep. 2013;13(2):252–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists. A review of their efficacy and tolerability. Diabetes Care. 2011;34(2):S279–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. United States Food and Drug Administration. FDA drug safety communication: FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines. 2013. Accessed 6 July 2021. Available http://www.fda.gov/Drugs/DrugSafety/ucm376389.htm.

Download references

Author information

Authors and Affiliations

  1. Vanderbilt University School of Nursing, Nashville, TN, USA

    Angelina Anthamatten

Authors
  1. Angelina Anthamatten
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angelina Anthamatten .

Editor information

Editors and Affiliations

  1. Assistant Professor, Vanderbilt University School of Nursing, Nashville, TN, USA

    K. Melissa Smith Hayes

  2. Director, Structural Heart Program, Director, Center for Advanced Heart Failure Therapy, Centennial Heart, Nashville, TN, USA

    Nicole R. Dellise

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Anthamatten, A. (2023). Diabetes and Heart Failure. In: Hayes, K.M.S., Dellise, N.R. (eds) Managing Heart Failure in Primary Care: A Case Study Approach. Springer, Cham. https://doi.org/10.1007/978-3-031-20193-6_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-20193-6_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-20192-9

  • Online ISBN: 978-3-031-20193-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation